• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

soliris

  1. Alexion rallies......

    Here's another good show by Alexion Pharma...! June-quarter financial results surpassed the consensus estimates of Wall Street analysts, powered by flagship SOLIRIS. No doubt, it's a much-needed boost for Alexion. Taking a cue from the impressive results, CEO Ludwig Hantson upgraded the outlook...
    • anonymous
    • Thread
    • alexion healthcare pharma soliris ultomiris
    • Replies: 1
    • Forum: Alexion

  2. Alexion product sales trend

    Sales trend of Soliris, Strensiq and Kanuma. Hope you find it useful -- More
    • anonymous
    • Thread
    • alexion pharmaceuticals drug sales soliris strensiq and kanuma
    • Replies: 1
    • Forum: Alexion

  3. R&D expense

    Apparently, Soliris drug sales are increasing. https://alphastreet.com/bite/4dac307 But how long can this company run on this? Given, the company has also announced that it is reducing the R&D expense for the year.
Top Bottom
Back